Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users

International Journal of Impotence Research

Volumn 20, Issue 6, 2008, Pages 566-573

  Aversa, A ^a   Rossi, F ^a   Francomano, D ^a   Bruzziches, R ^a   Bertone, C ^a   Santiemma, V ^a   Spera, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Flow mediated vasodilatation; HOMA index; Penile arteries; Recreational drug abuse; Veno occlusive plethysmography

Indexed keywords

CANNABIS; ENDOCANNABINOID; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PROLACTIN; TESTOSTERONE;

ADULT; ARTICLE; BLOOD PRESSURE; BRACHIAL ARTERY; CANNABIS ADDICTION; CONTROLLED STUDY; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM LESION; ERECTILE DYSFUNCTION; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASODILATATION; VENOOCCLUSIVE PLETHYSMOGRAPHY;

ADULT; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; MALE; MARIJUANA ABUSE; REGIONAL BLOOD FLOW; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 55849127787     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2008.43     Document Type: Article

References (43)

1. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-311.
2. Foresta C, Caretta N, Aversa A, Bettocchi C, Corona G, Mariani S et al. Erectile dysfunction: symptom or disease? J Endocrinol Invest 2004; 27: 80-95.
3. Shamloul R. Peak systolic velocities may be falsely low in young patients with erectile dysfunction. J Sex Med 2006; 3: 138-143.
4. Aversa A, Isidori AM, Caprio M, Cerilli M, Frajese V, Fabbri A. Penile pharmacotesting in diagnosing male erectile dysfunction: evidence for lack of accuracy and specificity. Int J Androl 2002; 25: 6-10.
5. La Pera G, Carderi A, Marianantoni Z, Peris F, Lentini M, Taggi F. Sexual dysfunction prior to first drug use among former drug addicts and its possible causal meaning on drug addiction: preliminary results. J Sex Med 2008; 5: 164-172.
6. Marihuana: A Signal of Misunderstanding, from: The Report of the National Commission on Marihuana and Drug Abuse, Commissioned by President Richard M. Nixon, March 1972. http://www.druglibrary.org/Schaffer/Library/studies/nc/ ncmenu.htm.
7. Celemajer DS. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 1997; 30: 325-333.
8. Hsueh WA, Lyon CJ, Quĩones MJ. Insulin resistance and the endothelium. Am J Med 2004; 117: 109-117.
9. Ferrannini E, Buzzicoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
10. Shen DC, Shieh SM, Fuh MM, Wu DA, Chen YD, Reaven GM. Resistance to insulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988; 66: 580-583.
11. Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 2002; 14: 245-250.
12. Greco EA, Pili M, Bruzziches R, Corona G, Spera G, Aversa A. Testosterone:estradiol ratio changes associated with longterm tadalafil administration: a pilot study. J Sex Med 2006; 3: 716-722.
13. Aversa A, Bonifacio V, Moretti C, Fraiese G, Fabbri A. Redosing of prostaglandin-E1 versus prostaglandin-E1 plus phentolamine in male erectile dysfunction: a dynamic color power Doppler study. Int J Impot Res 2000; 12: 33-40.
14. Aversa A, Sarteschi LM. The role of penile color-duplex ultrasound for the evaluation of erectile dysfunction. J Sex Med 2007; 4: 1437-1447.
15. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003; 166: 345-349.
16. Pasimeni G, Ribaudo MC, Capoccia D, Rossi F, Bertone C, Leonetti F et al. Non-invasive evaluation of endothelial dysfunction in uncomplicated obesity: relationship with insulin resistance. Microvasc Res 2006; 71: 115-120.
17. Sakamoto H, Nagata M, Saito K, Okumura T, Yoshida H. Anatomic variations of cavernous arteries and their effect on measurement of hemodynamic parameters: a power Doppler study. Urology 2004; 63: 539-544.
18. Radikova Z, Koska J, Huckova M, Ksinantova L, Imrich R, Vigas M et al. Insulin sensitivity indices: a proposal of cut-off points for simple identification of insulin-resistant subjects. Exp Clin Endocrinol Diabetes 2006; 114: 249-256.
19. Brambilla F. Droghe di abuso e sistema neuroendocrino: aspetti clinici. In: Basi biologiche e farmacologiche delle tossicodipendendenze. Gori E and Muller EE (eds), Phytagora Press: Milan, 1992, p 199.
20. de Miguel R, Romero J, Munoz RM, Garcia-Gil L, Gonzalez S, Villanua MA et al. Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. Biochem Pharmacol 1998; 56: 1331-1338.
21. Sethi BB, Trivedi JK, Kumar P, Gulati A, Agarwal AK, Sethi N. Anti-anxiety effect of cannabis: involvement of central benzodiazepine receptors. Biol Psychiatry 1986; 21: 3-10.
22. Maccarrone M, Wenger T. Effects of cannabinoids on hypothalamic and reproductive function. Handb Exp Pharmacol 2005; 168: 555-571.
23. Schaefer CF, Gunn CG, Dubowski KM. Normal plasma testosterone concentrations after marihuana smoking. N Engl J Med 1975; 292: 867-868.
24. Paton WD. Pharmacology of marijuana. Ann Rev Pharmacol 1975; 15: 191-220.
25. Cohen S. The 94-day cannabis study. Ann NY Acad Sci 1976; 282: 211-220.
26. Coggins WJ, Swenson EW, Dawson WW, Fernandez-Salas A, Hernandez-Bolanos J, Jiminez-Antillon CF et al. Health status of chronic heavy cannabis users. Ann NY Acad Sci 1976; 282: 148-161.
27. Rawitch AB, Schultz GS, Ebner KE, Vardaris RM. Competition of delta 9-tetrahydrocannabinol with estrogen in rat uterine estrogen receptor binding. Science 1977; 197: 1189-1191.
28. Sauer MA, Rifka SM, Hawks RL, Cutler Jr GB, Loriaux DL. Marijuana: interaction with the estrogen receptor. J Pharmacol Exp Ther 1983; 224: 404-407.
29. Zacharia LC, Gogos JA, Karayiorgou M, Jackson EK, Gillespie DG, Barchiesi F et al. Methoxyestradiols mediate the antimitogenic effects of 17beta-estradiol: direct evidence from catechol-O-methyltransferase-knockout mice. Circulation 2003; 108: 2974-2978.
30. Juan-Picó P, Fuentes E, Bermúdez-Silva FJ, Javier Díaz-Molina F, Ripoll C, Rodríguez de Fonseca F et al. Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell. Cell Calcium 2006; 39: 155-162.
31. Barbosa RM, Silva AM, Tome AR, Stamford JA, Santos RM, Rosario LM. Control of pulsatile 5-HT/insulin secretion from single mouse pancreatic islets by intracellular calcium dynamics. J Physiol 1998; 510(pt 1): 135-143.
32. Akiba Y, Kato S, Katsube K, Nakamura M, Takeuchi K, Ishii H et al. Transient receptor potential vanilloid subfamily 1 expressed in pancreatic islet beta cells modulates insulin secretion in rats. Biochem Biophys Res Commun 2004; 321: 219-225.
33. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
34. Laychock SG, Hoffman JM, Meisel E, Bilgin S. Pancreatic islet arachidonic acid turnover and metabolism and insulin release in response to delta-9-tetrahydrocannabinol. Biochem Pharmacol 1986; 35: 2003-2008.
35. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
36. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. RIO-Europe Study Group, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
37. Romano MR, Lograno MD. Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels. Br J Pharmacol 2006; 147: 917-925.
38. Lépicier P, Lagneux C, Sirois MG, Lamontagne D. Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts. Life Sci 2007; 81: 1373-1380.
39. Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Huffman JW et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007; 293: H2210-H2218.
40. McCollum L, Howlett AC, Mukhopadhyay S. Anandamide-mediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther 2007; 321: 930-937.
41. Ghasemi M, Sadeghipour H, Dehpour AR. Anandamide improves the impaired nitric oxide-mediated neurogenic relaxation of the corpus cavernosum in diabetic rats: involvement of cannabinoid CB1 and vanilloid VR1 receptors. BJU Int 2007; 100: 1385-1390.
42. Caldicott DG, Holmes J, Roberts-Thomson KC, Mahar L. Keep off the grass: marijuana use and acute cardiovascular events. Eur J Emerg Med 2005; 12: 236-244.
43. Jones RT. Cardiovascular effects of marijuana. J Clin Pharmacol 2002; 42: 58S-63S.